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EDUCATING THE PEDIATRIC BLOOD AND MARROW TRANSPLANT PA-
TIENTS AND FAMILIES WITH DIAGNOSES OF GENETIC VERSUS MALIG-
NANT DIAGNOSES
Allison-Thacker, J.1, Robinette, D.1, Kurtzberg, J.1 1Duke University
Medical Center, Durham, NC.
The Pediatric Blood and Marrow Transplant Program at Duke
transplants 100 patients each year with malignancies, blood dys-
crasias and immune deﬁciencies and metabolic disorders affecting
lysosomal and peroxisomal pathways (LSDs). Nurse Coordinators
(NC) are responsible for educating patients and caregivers about
the transplant process extending over a continuum throughout the
transplant process. Caregivers receive a Parent Handbook, detail-
ing the transplant process. The Nurse Coordinator utilizes a visual
tool, the Road to Transplant ﬂipchart, in a formal education
session. This stimulates in-depth discussion involving how a trans-
plant can affect the diagnosis, known risks, complications, and
beneﬁts of transplant and ends with a time for questions/answers.
A patient-speciﬁc Roadmap outlines the individual expected plan
of care. Pre-consenting sessions, including review of the written
consent form,help families become well informed and formulate
questions for the formal consenting session with the primary
physician. Tours of clinical facilities provide additional opportu-
nities to exchange educational information. In practice, Nurse
Coordinators have observed that the knowledge base is disparate
between metabolic and leukemic populations. By the time the
referral has been made for transplant, the leukemic population is
hospital savvy with a broad knowledge base. The metabolic families
differ in that the diagnosis and referral usually occurs simulta-
neously, giving limited time for families to understand the diag-
nosis and prognosis, let alone the complexities of the transplant
process. Transplantation of patients with LSDs is effective, partic-
ularly if performed early in the course of the disease. With the
advent of newborn screening, more patients will be referred to
transplant centers with these diagnoses. Education tools and ap-
proaches should be adapted to meet the needs of this unique
patient population.
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BLOOD AND MARROW TRANSPLANT NURSING JOURNAL CLUB: AN
EFFECTIVE METHOD FOR PROVIDING CONTINUING NURSING EDUCA-
TION
Anderson-Reitz, L.A.1, Brougher, L.I.1, Shaw, T.1 1Baylor Medical
Center/Baylor Charles A Sammons Cancer Center, Dallas, TX.
Purpose, Background, Rationale:
Providing a venue for continuing nursing education can be costly
and time consuming. FACT requires nurses who care for blood
and marrow transplant patients to be “formally trained” in all
aspects of their care. We sought a means to provide focused
nursing education within the specialty of blood and marrow trans-
plant that would help to assure expertise as well as expose nurses to
innovative evidence based practice.
We chose to develop a blood and marrow transplant nursing
journal club as a way to meet our goals for nursing education.
Journal clubs have been utilized for many years within the medical
community to discuss and evaluate research. The use of journal
clubs in nursing have become more prevalent with the push toward
evidence based practice.
Interventions:
We presented the concept of a journal club to the nurses in our
in-patient and out-patient units. The response was positive, so a
questionnaire was distributed asking for monthly topics. We chose
the most prevalent topics and developed a calendar for the coming
year. Each month a facilitator was identiﬁed and that individual/s
conducted a literature search on the chosen topic. Less experienced
nurses who had a desire to present were offered mentoring and
assistance by an advanced practice nurse. One to two medical or
nursing journal articles were chosen and distributed to the nursing
staff 1-2 weeks prior to journal club. Journal clubs were a mixture
of didactic presentation and general question and answer discus-
sions. The facilitator was also responsible for applying for CEUs
each month. The nurses who attended were then awarded 1.2
CEUs.
Evaluation:
Evaluations required for CEUs were completed each month.
Rankings were consistently in the outstanding range. The evalua-
tion forms also provided an avenue for nurses to list topics of
interest for future journal clubs.
Discussion:
We have found that a blood and marrow transplant nursing
journal club provides a relaxed and conducive place for nurses to
learn. Nurses are able to choose topics that are interesting and
relevant to their practice. Our journal club is open to other disci-
plines in the program which facilitates a healthy multidisciplinary
approach to topic discussion. We feel journal clubs are a very
effective, low cost means of meeting continuing nursing education
needs.
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BMT DISCHARGE NURSE: THE FORCE BEHIND THE DISCHARGE PRO-
CESS
Austria-Granada, M.L.R.1, Johnston, P.1, Dela Cruz, B.1,
Estepa-Estrella, J.M.A.1, Febryani, I.1 1UT MD Anderson Cancer
Center, Houston, TX.
Nursing is engaged in diverse functions that constantly thrive to
meet the needs of the patients and the healthcare system. Patients
who had blood or marrow transplant (BMT) have distinctive needs
and a point of paramount signiﬁcance is to prepare them to deal
with overwhelming tasks involved after discharge. Additionally,
with emerging number of inpatient admissions and lack of bed
availability, in line with the institution’s Project BED (Bringing
Efﬁcient Discharge), staffs were commissioned to function as dis-
charge nurses in the BMT department. They are utilized to address
these concerns and assist bedside nurses to fulﬁll a coordinated and
timely discharge.
For the past years, average discharge time in our unit is 1500,
which is beyond the established institutional discharge time of
1100. Patients requiring blood and electrolyte replacements, de-
layed discharge teachings and line exchanges are some of the
common reasons for late discharges. The discharge nurses then
collaborated with various disciplines to maintain plan of care and
develop strategies to ameliorate discharge outcomes. Since its in-
ception on April 17, 2006, discharge time for BMT markedly
improved to 1335 and with the aid of the multidisciplinary team
the earliest discharge time for one patient is 0817 am.
The discharge nurses present a vast impact in improving the
discharge process in the BMT ﬂoor. Aside from formulating tools
to monitor discharge statistics, evaluating data, proposing and
implementing quality improvement projects, they also serve as
frontline educators managing admission and discharge teachings.
They facilitate care of off- ﬂoor patients and act as resources by
doing frequent visits and being available when called upon. Lastly,
they perform post discharge telephone calls to ensure safe transi-
tion to home and complete patient satisfaction surveys.
Audit tools, metrix indicating monthly average discharge time,
length of stay for each transplant, reasons for late discharges will be
presented.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC LU-
PUS ERYTHEMATOSUS: UNIQUE CHALLENGES AND STRATEGIES FOR
THE NURSING CARE TEAM
Babb, R.1, Shelburne, N.2, Castro, K.2, Krumlauf, M.1, Pavletic, S.Z.1
1Experimental Transplantation and Immunology Branch, Center for
Cancer Research, National Cancer Institute, Bethesda, MD; 2Nursing
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and Patient Care Services, Mark O. Hatﬁeld Clinical Research Center,
National Institutes of Health, Bethesda, MD.
Clinical trials are being conducted to evaluate the safety and
efﬁcacy of hematopoietic stem cell transplantation (HSCT) as a
therapy for patients with severe, refractory systemic lupus ery-
thematosus (SLE). Nurses coordinating the care of patients receiv-
ing HSCT may be unfamiliar with aggressive systemic autoim-
mune diseases, such as refractory SLE. The presentations of SLE
can include nephrotoxicity, pulmonary toxicity, permanent alter-
ations in mobility, cognitive impairment, blindness, chronic pain,
as well as the many complications of long term immunosuppressive
therapy. Such problems present intense and unanticipated chal-
lenges for the medical team and affect many aspects of a patient’s
physical and emotional well being.
The purpose of this project is to share our experience using a
nurse led Collaborative Care Model. The model highlights impli-
cations for the multidisciplinary care team, nursing education and
support, and resource utilization. It also provides a template for
utilizing patient resources not previously identiﬁed.
Complex and serious problems are an inherent part of SLE and
present different dynamics and chronicity when compared to typ-
ical hematology/oncology HSCT patients. Therefore, a care man-
agement model promoting collaborative relationships within a
multidisciplinary team was essential. The nursing led team, which
included research nurses, clinical nurses, clinical nurse specialists,
nurse managers, and nurse practitioners, was instrumental in the
Collaborative Care Model.
At our research center, this model was utilized to coordinate the
HSCT care of 8 patients with severe SLE. The research nurse
functioned as team coordinator, maintaining constant communi-
cation between the patient, transplant team, rheumatology service
and other specialties involved in the plan of care. The research
nurse ensured protocol compliance, ongoing staff education and
protection of human subjects. Interdisciplinary meetings were held
weekly to provide a forum for discussion and dissemination of
information. The model facilitated a partnership between nurses,
medical specialists and ﬁnancial, social, and community services
which ensured timely access to resources and support.
As the role of HSCT is evaluated in additional non-malignant
disorders, nurses will be faced with new challenges and unfamiliar
patient populations. HSCT centers may ﬁnd our Collaborative
Care Model a way to effectively utilize resources and manage
complex patients.
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TREATMENT OF ACUTE GRAFT VS. HOST DISEASE AFTER UNRELATED
DONOR UMBILICAL CORD BLOOD TRANSPLANTATION IN PEDIATRIC
PATIENTS
Baker, E.J.2, Frey, M.A.2, Kurtzberg, J.2 1Duke University Hospital,
Durham, NC; 2The Duke Pediatric Blood and Marrow Transplant
Program, Durham, NC.
Unrelated donor umbilical cord blood (UCB) has been shown to
be an important source of hematopoietic stem cells for transplan-
tation in patients unable to ﬁnd a fully matched related or unre-
lated donor. UCB is readily available and can be used with partial
HLA matching allowing access to donors for transplantation for
the many patients who will never ﬁnd or who do not have time to
ﬁnd a perfectly matched bone marrow donor. Over the past 13
years, our program has performed 600 UCBT in pediatric pa-
tients with hematological malignancies, bone marrow failure syn-
dromes, immunodeﬁciency syndromes, hemoglobinopathies and
inborn errors of metabolism. In two thirds of these transplants,
donor/recipient pairs were matched at 4/6 HLA loci. Grades II-IV
acute graft-versus-host disease (GvHD) occured in approximately
35-40% of patients underdoing UCBT despite prophylactic ther-
apy. We have utilized cyclosporine/methylprednisolone or, more
recently cyclosporine/cellcept (MMF) for GvHD prophylaxis.
Many patients experience erythroderma with fever between days
11-25 post transplant, before neutrophil engraftment which may
represent engraftment syndrome or early GvHD. We have treated
this syndrome with a pulse of methylprednisolone (500mg/m2/
dose IV q12h X 4 doses for patients receiving conventional dose
steroids for GvHD prophylaxis, or 1-2mg/kg/day divided BID for
those on MMF). Responding patients taper steroids over the next
few weeks. Those that don’t respond or who experience rash or
diarrhea after initial steroid taper clearly have acute GvHD and are
switched to FK-506 with dacluzimab. Most patients are controlled
on this regimen which is then slowly weaned over the next 3-4
months. For the small number of patients (5%) not responding
to this therapy, inﬂiximab is added. For those failing inﬂiximab,
alternative therapies are pursued. GvHD after UCBT is different
than that after bone marrow transplantation in that rashes are
milder and progression to the GI tract is rarer and more indolent.
Liver GvHD is rare. This presentation will discuss the clinical
presentations, treatment and overall outcomes of pediatric patients
undergoing UCBT developing acute GvHD.
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OUTCOMES OF PEDIATRIC PATIENTS TRANSPLANTED A SECOND TIME
AFTER EXPERIENCING GRAFT FAILURE WITH UNRELATED DONOR
UMBILICAL CORD BLOOD TRANSPLANTATION
Baker, J.H.1, Martin, P.L.1, Driscoll, T.1, Szabolcs, P.1, Allison, J.1,
Gurganus, K.1, Ciocci, G.1, Parikh, S.1, Prasad, V.1, Kurtzberg, J.1
1Duke University Medical Center, Durham, NC.
Approximately 20% of patients undergoing unrelated donor um-
bilical cord blood transplantation (UCBT) with a single cord blood
unit, will fail to engraft. The causes for graft failure include host
immunological rejection with or without autologous reconstitu-
tion, infection and relapse. Over the past 13 years, the Pediatric
Blood and Marrow Transplant Program at Duke has transplanted
600 Pediatric patients with malignant diagnoses, lysosomal stor-
age diseases, hemoglobinopathies, congenital marrow failure syn-
dromes and congenital immunodeﬁciency syndromes with unre-
lated donor UCB. Thirty of these patients have experienced graft
failure and have been treated with a second UCBT as salvage
therapy. Median age of the group was 5 years (range 1-20 years),
73% were male, 40% non-Caucasian and 43% had malignant
diagnoses. All but 2 patients received myeloablative therapy as
preparation for their ﬁrst transplant. The median cell dose for the
ﬁrst transplant was 4.410e7/kg (range 0.99-21.25). 60% of the
ﬁrst transplants were matched at 4/6 HLA loci while 32% were
matched at 5/6 loci. Reasons for graft failure after transplant #1
were persistent leukemic disease (n1), autologous recovery
(n12) and graft rejection with aplasia (n17). All patients were
prepared for their second transplant with reduced intensity therapy
including cyclosphosphamide 30mg/kg/dose daily x 2, ATG (horse
or rabbit) x 3 days /- ﬂudarabine, campath or low dose TBI. Cell
doses were similar to the ﬁrst transplant and HLA disparity slightly
greater. All patients were supported with G-CSF mobilized, irra-
diated granulocytes during their second aplasia. Twenty patients
(66%) engrafted with donor cells after a second (n18) or third
(n2) transplant. Two patients died before engraftment, 1 re-
mained in relapse, and the others experienced second autologous
reconstitution. Eleven patients (35%) remain durably engrafted,
surviving long term with a median follow-up of 2 years (range
1-7 years). We conclude that a second UCBT after primary graft
failure offers a chance for long term survival in a signiﬁcant num-
ber of patients.
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AN EXPLORATORY ANALYSIS OF SYMPTOM EXPERIENCE AT DAYS 30
AND 100 FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (AHSCT)
Bevans, M.F.1, Mitchell, S.A.1, Marden, S.1 1Clinical Center, National
Institutes of Health, Bethesda, MD.
Background: Despite advances in AHSCT treatment and sup-
portive care, post-transplant complications are common and char-
acterization of patients’ symptom experience is needed before de-
veloping symptom management strategies. Purpose: Using the
Symptom Management Model1 as a theoretical foundation, this
exploratory analysis examined patients’ symptom perception and
symptom evaluation in the early period following AHSCT.Meth-
ods: Data were collected as part of a prospective study examining
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